

CLAIM SUMMARY DOCUMENT

Claims 1-12 (Previously Canceled)

13. (Previously Presented) A method of improving mucus clearance comprising administering to the respiratory tract of a patient in need of such treatment an effective amount of a polysaccharide having about the same number of hydrogen bonding sites as dextran.

14. (Currently Amended) A method of improving mucus clearance comprising administering to the respiratory tract of a patient in need of such treatment an effective amount of a polysaccharide having sugar moieties that stereochemically complement the oligosaccharide moieties native to the respiratory tract mucins ~~in the manufacture of a medicament to improve mucus clearance.~~

15. (Previously Presented) The method of claim 14, wherein the polysaccharide comprises oligomers of galactose and fucose and the amino sugars glucosamine and galactosamine.

16. (Previously Presented) The method of claim 13, wherein the polysaccharide is administered in admixture with a pharmaceutically acceptable diluent or carrier.

17. (Currently Amended) The method of claim 16, wherein the diluent is sodium chloride or ringer Ringer solution.

18. (Previously Presented) The method of claim 13, wherein the polysaccharide is administered to the respiratory tract topically or by aerosol.

19. (Previously Presented) The method of claim 13, wherein the polysaccharide is present in the respiratory secretion at a concentration of about 4 mg/ml to about 40 mg/ml.

20. (Previously Presented) The method of claim 14, wherein the polysaccharide is administered in admixture with a pharmaceutically acceptable diluent or carrier.

*B
CONT'D*

21. (Currently Amended) The method of claim 20, wherein the diluent is sodium chloride or ringer Ringer solution.

22. (Previously Presented) The method of claim 14, wherein the polysaccharide is administered to the respiratory tract topically or by aerosol.

23. (Previously Presented) The method of claim 14, wherein the polysaccharide is present in the respiratory secretion at a concentration of about 4 mg/ml to about 40 mg/ml.

24. (Previously Presented) A method of treating lung disease associated with impaired mucus clearance comprising administering to the respiratory tract of a patient in need of such treatment an effective amount of a polysaccharide having about the same number of hydrogen bonding sites as dextran.

25. (Previously Presented) The method of claim 24, wherein the lung disease is cystic fibrosis, chronic bronchitis, bronchiectasis or bronchial asthma.

*B
CONTD*

26. (Previously Presented) A method of treating lung disease associated with impaired mucus clearance comprising administering to the respiratory tract of a patient in need of such treatment an effective amount of a polysaccharide having sugar moieties that stereochemically complement the oligosaccharide moieties native to the respiratory tract mucins in the manufacture of a medicament to improve mucus clearance.

27. (Previously Presented) The method of claim 26, wherein the polysaccharide comprises oligomers of galactose and fucose and the amino sugars glucosamine and galactosamine.

28. (Previously Presented) The method of claim 26, wherein the lung disease is cystic fibrosis, chronic bronchitis, bronchiectasis or bronchial asthma.

29. (Previously Presented) A method of improving mucus clearability in a patient having cystic fibrosis comprising administering to the respiratory tract of a patient in need of such treatment an effective amount of a polysaccharide having about the same number of hydrogen bonding sites as dextran.

30. (Previously Presented) The method of claim 29, further comprising the step of assessing liquification of secretions of said patient following treatment.

31. (Previously Presented) The method of claim 29, further comprising the step of assessing viscosity and elasticity of sputum of said patient following the treatment.

*B
CONT'D*
32. (Previously Presented) The method according to claim 29, wherein the polysaccharide is present in the respiratory secretion at a concentration of about 4 mg/ml to about 40 mg/ml.

33. (Previously Presented) A method of improving mucus clearability in a patient having cystic fibrosis comprising administering to the respiratory tract of a patient in need of such treatment an effective amount of a polysaccharide having sugar moieties that stereochemically complement the oligosaccharide moieties native to the respiratory tract mucins in the manufacture of a medicament to improve mucus clearance.

34. (Previously Presented) The method of claim 33, wherein the polysaccharide comprises oligomers of galactose and fucose and the amino sugars glucosamine and galactosamine.

35. (Previously Presented) The method of claim 33, further comprising the step of assessing liquification of secretions of said patient following treatment.

36. (Previously Presented) The method of claim 33, further comprising the step of assessing viscosity and elasticity of sputum of said patient following the treatment.

37. (Previously Presented) The method according to claim 33, wherein the polysaccharide is present in the respiratory secretion at a concentration of about 4 mg/ml to about 40 mg/ml.

*PB
Concl!!*